Urogen Pharma Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
234
- Stock Symbol
-
URGN
- Investments
-
2
- Share Price
-
$4.19
- (As of Friday Closing)
Urogen Pharma General Information
Description
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Contact Information
Website
www.urogen.comCorporate Office
- 400 Alexander Park Drive
- 4th Floor
- Princeton, NJ 08540
- United States
Corporate Office
- 400 Alexander Park Drive
- 4th Floor
- Princeton, NJ 08540
- United States
Urogen Pharma Timeline
Urogen Pharma Stock Performance
As of 23-May-2025, Urogen Pharma’s stock price is $4.19. Its current market cap is $193M with 46.1M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.19 | $4.08 | $3.42 - $20.70 | $193M | 46.1M | 1.01M | -$3.18 |
Urogen Pharma Financials Summary
As of 31-Mar-2025, Urogen Pharma has a trailing 12-month revenue of $91.9M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 396,506 | 321,770 | 415,120 | 182,624 |
| Revenue | 91,871 | 90,398 | 82,713 | 64,357 |
| EBITDA | (129,282) | (119,236) | (84,545) | (98,711) |
| Net Income | (138,431) | (126,874) | (102,244) | (109,783) |
| Total Assets | 247,618 | 285,711 | 178,311 | 135,619 |
| Total Debt | 124,949 | 123,387 | 99,395 | 99,123 |
Urogen Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Urogen Pharma Comparisons
Industry
Financing
Details
Urogen Pharma Competitors (16)
One of Urogen Pharma’s 16 competitors is Cullgen, a Venture Capital-Backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cullgen | Venture Capital-Backed | San Diego, CA | ||||
| Bluebird Bio | Formerly VC-backed | Somerville, MA | ||||
| Galapagos (Biotechnology) | Formerly VC-backed | Mechelen, Belgium | ||||
| Xenetic Bioscience | Corporation | Framingham, MA | ||||
| Polaris Group (California) | Formerly PE-Backed | Grand Cayman, Cayman Islands |
Urogen Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Urogen Pharma Patents
Urogen Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250032409-A1 | Treatment of low-grade intermediate-risk non-muscle-invasive bladder cancer with a thermally gelling pharmaceutical composition containing mitomycin | Pending | 25-Jul-2023 | ||
| US-20240382420-A1 | Immunomodulating treatments of body cavities | Active | 16-May-2023 | ||
| US-12263245-B2 | Immunomodulating treatments of body cavities | Active | 16-May-2023 | ||
| US-20240100019-A1 | Compositions comprising a thermoreversible hydrogel, and having an extended in-use period | Inactive | 28-Sep-2022 | ||
| US-11576744-B2 | Thermosensitive bio-adhesive hydrogel for removal of ureteral and renal stones | Active | 25-Mar-2021 | A61B90/04 |
Urogen Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Urogen Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Urogen Pharma Investments & Acquisitions (2)
Urogen Pharma’s most recent deal was a Corporate Asset Purchase with IconOVir (Portfolio of Oncolytic Virus Assets in United States) for . The deal was made on 14-Feb-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| IconOVir (Portfolio of Oncolytic Virus Assets in United States) | 14-Feb-2025 | Corporate Asset Purchase | Buildings and Property | ||
| Telormedix | 01-Jan-2015 | Merger/Acquisition | Biotechnology |
Urogen Pharma ESG
Risk Overview
Risk Rating
Updated April, 01, 2025
36.12 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,631
Rank
Percentile
Pharmaceuticals
Industry
of 843
Rank
Percentile
Biotechnology
Subindustry
of 365
Rank
Percentile
Urogen Pharma FAQs
-
When was Urogen Pharma founded?
Urogen Pharma was founded in 2004.
-
Where is Urogen Pharma headquartered?
Urogen Pharma is headquartered in Princeton, NJ.
-
What is the size of Urogen Pharma?
Urogen Pharma has 234 total employees.
-
What industry is Urogen Pharma in?
Urogen Pharma’s primary industry is Drug Delivery.
-
Is Urogen Pharma a private or public company?
Urogen Pharma is a Public company.
-
What is Urogen Pharma’s stock symbol?
The ticker symbol for Urogen Pharma is URGN.
-
What is the current stock price of Urogen Pharma?
As of 23-May-2025 the stock price of Urogen Pharma is $4.19.
-
What is the current market cap of Urogen Pharma?
The current market capitalization of Urogen Pharma is $193M.
-
What is Urogen Pharma’s current revenue?
The trailing twelve month revenue for Urogen Pharma is $91.9M.
-
Who are Urogen Pharma’s competitors?
Cullgen, Bluebird Bio, Galapagos (Biotechnology), Xenetic Bioscience, and Polaris Group (California) are some of the 16 competitors of Urogen Pharma.
-
What is Urogen Pharma’s annual earnings per share (EPS)?
Urogen Pharma’s EPS for 12 months was -$3.18.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
